This page is intended to provide reference information on AbbVie UK medicines for UK members of the public only.
Reference Information for AbbVie UK Medicines
In the list below, you can access links to the Electronic Medicines Compendium (eMC), an external resource which provides information about medicines available in the UK.
HUMIRA® (adalimumab)
United Kingdom:
SKYRIZI® (risankizumab)
United Kingdom:
RINVOQ®(upadacitinib)
United Kingdom:
VENCLYXTO® (venetoclax)
United Kingdom:
DUODOPA® (levodopa/carbidopa intestinal gel)
United Kingdom:
BOTOX® (botulinum toxin type A)
United Kingdom:
AQUIPTA®▼ (atogepant)
United Kingdom:
OZURDEX® (Dexamethasone 0.7mg intravitreal implant)
United Kingdom:
TEPKINLY®▼(Epcoritimab)
United Kingdom:
Reporting of side effects:
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet.
You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores. Adverse events should also be reported to AbbVie at GBPV@abbvie.com
By reporting side effects you can help provide more information on the safety of these medicines.
For medicines with black triangle:
▼ means the medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See https://yellowcard.mhra.gov.uk for how to report side effects or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores. Adverse events should also be reported to AbbVie at GBPV@abbvie.com
AbbVie Ltd
AbbVie House
Vanwall Business Park
Vanwall Road
Maidenhead
Berkshire
SL6 4UB
UK Telephone: 01628 561090
UK-ABBV-240369. Date of preparation: December 2024
Copyright © 2024 AbbVie Ltd. All rights reserved. Registered Number: 08004972 England.